Pixel-by-Pixel Comparison of Volume Transfer Constant and Estimates of Cerebral Blood Volume from Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast-Enhanced MR Imaging in High-Grade Gliomas

REFERENCES

1. 1.↵
   2. Burger PC

   . Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin Oncol 1986;13:16–26

   PubMed
2. 2.↵
   2. Lüdemann L,
   3. Warmuth C,
   4. Plotkin M, et al

   . Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H2(15)O positron emission tomography. Eur J Radiol 2009;70:465–74

   CrossRefPubMed
3. 3.↵
   2. Patankar TF,
   3. Haroon HA,
   4. Mills SJ, et al

   . Is volume transfer coefficient (Ktrans) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 2005;26:2455–65

   Abstract/FREE Full Text
4. 4.↵
   2. Mills SJ,
   3. Patankar TA,
   4. Haroon HA, et al

   . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853–58

   Abstract/FREE Full Text
5. 5.↵
   2. Bisdas S,
   3. Kirkpatrick M,
   4. Giglio P, et al

   . Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 2009;30:681–88

   Abstract/FREE Full Text
6. 6.↵
   2. Cao Y,
   3. Tsien CI,
   4. Nagesh V, et al

   . Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006;64:876–85

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Tofts PS,
   3. Brix G,
   4. Buckley DL, et al

   . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Law M,
   3. Yang S,
   4. Babb JS, et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

   Abstract/FREE Full Text
9. 9.↵
   2. Provenzale JM,
   3. York G,
   4. Moya MG, et al

   . Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. AJR Am J Roentgenol 2006;187:1036–42

   CrossRefPubMed
10. 10.↵
    2. Louis DN,
    3. Ohgaki H,
    4. Wiestler OD, et al

    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Paulson ES,
    3. Schmainda KM

    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Boxerman JL,
    3. Schmainda KM,
    4. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67

    Abstract/FREE Full Text
13. 13.↵
    2. Wells WM 3rd.,
    3. Viola P,
    4. Atsumi H, et al

    . Multi-modal volume registration by maximization of mutual information. Med Image Anal 1996;1:35–51

    CrossRefPubMed
14. 14.↵
    2. Aronen HJ,
    3. Gazit IE,
    4. Louis DN, et al

    . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Bruening R,
    3. Kwong KK,
    4. Vevea MJ, et al

    . Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831–40

    Abstract
16. 16.↵
    2. Haroon HA,
    3. Patankar TF,
    4. Zhu XP, et al

    . Comparison of cerebral blood volume maps generated from T2* and T1 weighted MRI data in intra-axial cerebral tumours. Br J Radiol 2007;80:161–68

    Abstract/FREE Full Text
17. 17.↵
    2. Jalali S,
    3. Chung C,
    4. Foltz W, et al

    . MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol 2014;16:868–79

    Abstract/FREE Full Text
18. 18.↵
    2. Sorensen AG,
    3. Batchelor TT,
    4. Zhang WT, et al

    . A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69:5296–300

    Abstract/FREE Full Text
19. 19.↵
    2. Fatterpekar GM,
    3. Galheigo D,
    4. Narayana A, et al

    . Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum—use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol 2012;198:19–26

    CrossRefPubMed
20. 20.↵
    2. Shin KE,
    3. Ahn KJ,
    4. Choi HS, et al

    . DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma. Clin Radiol 2014;69:e264–72

    CrossRefPubMed
21. 21.↵
    2. Sugahara T,
    3. Korogi Y,
    4. Tomiguchi S, et al

    . Post-therapeutic intra-axial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–09

    Abstract/FREE Full Text
22. 22.↵
    2. Mangla R,
    3. Singh G,
    4. Ziegelitz D, et al

    . Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010;256:575–84

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Yang FY,
    3. Ko CE,
    4. Huang SY, et al

    . Pharmacokinetic changes induced by focused ultrasound in glioma-bearing rats as measured by dynamic contrast-enhanced MRI. PLoS One 2014;9:e92910

    CrossRefPubMed
24. 24.↵
    2. Guo JY,
    3. Reddick WE,
    4. Rosen MA, et al

    . Dynamic contrast-enhanced magnetic resonance imaging parameters independent of baseline T10 values. Magn Reson Imaging 2009;27:1208–15

    CrossRefPubMed
25. 25.↵
    2. Jung SC,
    3. Yeom JA,
    4. Kim JH, et al

    . Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 2014;35:1103–10

    Abstract/FREE Full Text
26. 26.↵
    2. Essig M,
    3. Shiroishi MS,
    4. Nguyen TB, et al

    . Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 2013;200:24–34

    CrossRefPubMedWeb of Science